JPRN-UMIN000031203
Recruiting
未知
Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomy - Safety and efficacy of nab-P + Geme in the patients with recurrent pancreatic cancer
niversity of Yamanashi0 sites30 target enrollmentFebruary 9, 2018
Conditionspancreatic cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- pancreatic cancer
- Sponsor
- niversity of Yamanashi
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients with allergy for nab\-paclitaxel and gemcitabine 2\) Patients with severe infection 3\) Patients who are considered to be inappropriate for this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24
Completed
Not Applicable
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancerunresectable pancreas cancerJPRN-UMIN000013206Yokohama City University Hospital Oncology
Active, not recruiting
Phase 1
Study of Nab-paclitaxel and Gemcitabine in Elderly Patients with Pancreatic CancerMetastatic pancreatic cancerMedDRA version: 17.1 Level: PT Classification code 10033610 Term: Pancreatic carcinoma metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003596-27-ESAsociación de Oncología Médica del Hospital de Cruces (ASONMEC)80
Recruiting
Phase 2
Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary siteCarinoma of unknown primary site(CUP)JPRN-UMIN000016728Teikyo University School of Medicine30
Completed
Phase 2
Phase II study of gemcitabine plus nab-Pacletaxel as second-line therapy after FOLFIRINOX for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000016624Gifu University Hospital30